ANN-MARIE COBB: Open Payments
NPI 1104927748 · LAPLATA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,694 in 71 payments from 24 companies in 2025. Trend: 2023 $2,384 · 2024 $5,060 · 2025 $3,694
Food & beverage: $1,869Travel & lodging: $1,757Education: $68
| Company | Payments | Amount |
|---|---|---|
| Eli Lilly and Company | 3 | $1,212 |
| Novartis Pharmaceuticals Corporation | 7 | $943 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $270 |
| SCPHARMACEUTICALS INC. | 9 | $265 |
| Novo Nordisk Inc | 7 | $142 |
| Lilly USA, LLC | 6 | $137 |
| AstraZeneca Pharmaceuticals LP | 3 | $85 |
| Zimmer Biomet Holdings, Inc. | 1 | $77 |
| OPKO Pharmaceuticals, LLC | 3 | $68 |
| AKEBIA THERAPEUTICS INC | 2 | $54 |
Products named: Kerendia, FUROSCIX, Ozempic, MOUNJARO, ROSA, RAYALDEE, JARDIANCE, Vafseo.
Industry payments across MD — which companies pay providers there.
